Acadia Gets European Commission Nod for Daybu in Rett Syndrome

ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.

Zacks Investment Research • Aug 24, 2026

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and ad.

Business Wire • Aug 24, 2026

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data

ACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer's disease psychosis during a discussion hosted by Canaccord Genuity.

MarketBeat • Aug 12, 2026

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Zacks Investment Research • Aug 7, 2026

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research • Aug 6, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.

Zacks Investment Research • Aug 5, 2026

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.

Zacks Investment Research • Aug 6, 2026

ACADIA Pharmaceuticals Q2 Earnings Call Highlights

ACADIA Pharmaceuticals NASDAQ: ACAD reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and Parkinson's disease psychosis treatment NUPLAZID increased.

MarketBeat • Aug 4, 2026

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another q.

Business Wire • Aug 4, 2026